|
A blood-based proteomic classifier for the molecular characterization of pulmonary nodules.
|
24132637
|
Sci Transl Med
|
|
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
|
29622464
|
Cancer Cell
|
|
A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
|
30487137
|
Cancer Res.
|
|
A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes.
|
17251920
|
Nat. Rev. Cancer
|
|
A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.
|
27596916
|
Ann. Thorac. Surg.
|
|
A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.
|
29625054
|
Cell
|
|
A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.
|
30268436
|
Cell Syst
|
|
A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.
|
28855354
|
Clin. Cancer Res.
|
|
A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.
|
30376426
|
J. Clin. Oncol.
|
|
Aberrant methylation of p21 gene in lung cancer and malignant pleural mesothelioma.
|
21709715
|
Acta Med. Okayama
|
|
Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers.
|
17096329
|
Int. J. Cancer
|
|
Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer.
|
29864375
|
Am. J. Respir. Crit. Care Med.
|
|
An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury.
|
21454801
|
Am. J. Respir. Cell Mol. Biol.
|
|
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.
|
29625055
|
Cell
|
|
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
|
16221779
|
N. Engl. J. Med.
|
|
Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.
|
29496499
|
Chest
|
|
Autoantibodies against tumor-associated antigens in the early detection of lung cancer.
|
27565936
|
Lung Cancer
|
|
Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation.
|
24722292
|
Cell Death Dis
|
|
BAP1 regulates IP3R3-mediated Ca<sup>2+</sup> flux to mitochondria suppressing cell transformation.
|
28614305
|
Nature
|
|
Biomarkers and molecular testing for early detection, diagnosis, and therapeutic prediction of lung cancer.
|
23566973
|
Thorac Surg Clin
|
|
Biomarkers and prognostic factors for mesothelioma.
|
23977535
|
Ann Cardiothorac Surg
|
|
Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.
|
24623168
|
Eur J Cardiothorac Surg
|
|
Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin.
|
21159167
|
Mol. Cancer
|
|
Blood-based lung cancer biomarkers identified through proteomic discovery in cancer tissues, cell lines and conditioned medium.
|
26279647
|
Clin Proteomics
|
|
Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma.
|
22552293
|
Cancer Res.
|
|
CARP-1 functional mimetics are a novel class of small molecule inhibitors of malignant pleural mesothelioma cells.
|
24598827
|
PLoS ONE
|
|
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
|
29625048
|
Cell
|
|
Cellular and molecular parameters of mesothelioma.
|
16795078
|
J. Cell. Biochem.
|
|
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.
|
29622466
|
Cancer Cell
|
|
Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules.
|
26896032
|
J Thorac Oncol
|
|
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.
|
30078747
|
Cancer Cell
|
|
Comprehensive Characterization of Cancer Driver Genes and Mutations.
|
29625053
|
Cell
|
|
Comprehensive Characterization of Cancer Driver Genes and Mutations.
|
30096302
|
Cell
|
|
Comprehensive Characterization of Cancer Driver Genes and Mutations.
|
29625053
|
Cell
|
|
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.
|
30380420
|
Cell Rep
|
|
Comprehensive molecular profiling of lung adenocarcinoma.
|
25079552
|
Nature
|
|
CREB-induced inflammation is important for malignant mesothelioma growth.
|
25111229
|
Am. J. Pathol.
|
|
Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters.
|
16966607
|
Proc. Natl. Acad. Sci. U.S.A.
|
|
Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma.
|
21620418
|
J. Thorac. Cardiovasc. Surg.
|
|
Diagnosis and prognosis-review of biomarkers for mesothelioma.
|
28706912
|
Ann Transl Med
|
|
Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.
|
19273703
|
J. Clin. Oncol.
|
|
Differential N-Glycosylation Patterns in Lung Adenocarcinoma Tissue.
|
26322380
|
J. Proteome Res.
|
|
Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung.
|
15639718
|
Lung Cancer
|
|
DNA copy number gains in malignant pleural mesothelioma.
|
26722325
|
Oncol Lett
|
|
DNA methylation profile of 28 potential marker loci in malignant mesothelioma.
|
17659810
|
Lung Cancer
|
|
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
|
29617662
|
Cell Rep
|
|
Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool.
|
23056237
|
PLoS ONE
|
|
Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma.
|
21673066
|
Clin. Cancer Res.
|
|
Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma.
|
29980786
|
Oncogene
|
|
ERK2 is essential for the growth of human epithelioid malignant mesotheliomas.
|
21710492
|
Int. J. Cancer
|
|
Evaluation of clonal origin of malignant mesothelioma.
|
25471750
|
J Transl Med
|
|
Exosomal miR-16-5p as a target for malignant mesothelioma.
|
31406207
|
Sci Rep
|
|
Expression of Concern: HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
|
32169964
|
Clin. Cancer Res.
|
|
Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
|
24669013
|
Ann. Oncol.
|
|
Extracellular mRNA Detected by Tethered Lipoplex Nanoparticle Biochip for Lung Adenocarcinoma Detection.
|
27304243
|
Am. J. Respir. Crit. Care Med.
|
|
Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma.
|
29416614
|
Oncotarget
|
|
Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas.
|
23446998
|
Clin. Cancer Res.
|
|
Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.
|
30410729
|
F1000Res
|
|
Fibulin-3 as a biomarker for pleural mesothelioma.
|
23301743
|
N. Engl. J. Med.
|
|
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
|
23050525
|
N. Engl. J. Med.
|
|
Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer.
|
20689445
|
J Thorac Oncol
|
|
Genomic and Functional Approaches to Understanding Cancer Aneuploidy.
|
29622463
|
Cancer Cell
|
|
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
|
29617664
|
Cell Rep
|
|
Genomic events associated with progression of pleural malignant mesothelioma.
|
18973227
|
Int. J. Cancer
|
|
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.
|
29617660
|
Cell Rep
|
|
Germline BAP1 mutations predispose to malignant mesothelioma.
|
21874000
|
Nat. Genet.
|
|
Germline BAP1 mutations induce a Warburg effect.
|
28665402
|
Cell Death Differ.
|
|
Heparanase inhibitors restrain mesothelioma.
|
30627323
|
Oncotarget
|
|
HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway.
|
17872495
|
Am. J. Respir. Cell Mol. Biol.
|
|
High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma.
|
25658628
|
J Thorac Oncol
|
|
High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.
|
27834213
|
Proc. Natl. Acad. Sci. U.S.A.
|
|
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
|
26733616
|
Clin. Cancer Res.
|
|
HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma.
|
28186988
|
Oncotarget
|
|
hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.
|
20160038
|
Cancer Res.
|
|
HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.
|
29311642
|
Oncogene
|
|
Identification of autoantibodies to ECH1 and HNRNPA2B1 as potential biomarkers in the early detection of lung cancer.
|
28638733
|
Oncoimmunology
|
|
Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE).
|
15777968
|
Lung Cancer
|
|
Increased osteonectin expression is associated with malignant transformation and tumor associated fibrosis in the lung.
|
15246191
|
Lung Cancer
|
|
Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin.
|
27486763
|
Oncotarget
|
|
Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.
|
28759042
|
Oncogene
|
|
Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.
|
29617661
|
Cell Rep
|
|
Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma.
|
28049629
|
Carcinogenesis
|
|
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
|
30322867
|
Cancer Discov
|
|
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
|
30322867
|
Cancer Discov
|
|
Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.
|
29579286
|
J. Natl. Cancer Inst.
|
|
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
|
28967920
|
Nat. Med.
|
|
lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer.
|
29622465
|
Cancer Cell
|
|
Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity.
|
19818970
|
J. Thorac. Cardiovasc. Surg.
|
|
Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.
|
29617658
|
Cell Rep
|
|
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.
|
29625051
|
Cell
|
|
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.
|
22980975
|
Cell
|
|
Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects.
|
19852844
|
Mol. Cancer
|
|
MESOMARK: a potential test for malignant pleural mesothelioma.
|
17289801
|
Clin. Chem.
|
|
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
|
25380601
|
Carcinogenesis
|
|
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
|
18093943
|
Proc. Natl. Acad. Sci. U.S.A.
|
|
Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma.
|
25657018
|
Cancer Prev Res (Phila)
|
|
Methylation profile landscape in mesothelioma: possible implications in early detection, disease progression, and therapeutic options.
|
25421663
|
Methods Mol. Biol.
|
|
microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer.
|
23945385
|
J Thorac Oncol
|
|
Molecular characterization of the peripheral airway field of cancerization in lung adenocarcinoma.
|
25705890
|
PLoS ONE
|
|
Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.
|
29617665
|
Cell Rep
|
|
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma.
|
31278276
|
Nat Commun
|
|
Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1.
|
31257023
|
Cell
|
|
Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex.
|
16243798
|
Clin. Cancer Res.
|
|
Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival.
|
19309490
|
Histopathology
|
|
Oncogenic Signaling Pathways in The Cancer Genome Atlas.
|
29625050
|
Cell
|
|
Onconase mediated NFKβ downregulation in malignant pleural mesothelioma.
|
21317924
|
Oncogene
|
|
Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway.
|
19047145
|
Cancer Res.
|
|
Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening.
|
20924114
|
Cancer Res.
|
|
Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma.
|
17493236
|
Histopathology
|
|
Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma.
|
17493236
|
Histopathology
|
|
Overexpression of EPH receptor B2 in malignant mesothelioma correlates with oncogenic behavior.
|
23887168
|
J Thorac Oncol
|
|
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
|
29596783
|
Cell Syst
|
|
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context.
|
29617668
|
Cell Rep
|
|
Pan-cancer analysis of whole genomes.
|
32025007
|
Nature
|
|
Pathogenic Germline Variants in 10,389 Adult Cancers.
|
29625052
|
Cell
|
|
Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.
|
28945830
|
Ann. Oncol.
|
|
Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells.
|
22761781
|
PLoS ONE
|
|
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.
|
29625049
|
Cell
|
|
Plasma Anti-Glycan Antibody Profiles Associated with Nickel level in Urine.
|
24737927
|
J Proteomics Bioinform
|
|
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.
|
26903362
|
J Thorac Oncol
|
|
Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population.
|
23568008
|
Cancer Biomark
|
|
Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
|
27447750
|
Oncotarget
|
|
Prediction of lung cancer using volatile biomarkers in breath.
|
17522431
|
Cancer Biomark
|
|
Pro-tumorigenic effects of miR-31 loss in mesothelioma.
|
20463022
|
J. Biol. Chem.
|
|
Pro-tumorigenic effects of miR-31 loss in mesothelioma.
|
20463022
|
J. Biol. Chem.
|
|
Processing and analysis of serum antibody binding signals from Printed Glycan Arrays for diagnostic and prognostic applications.
|
22112531
|
Int J Bioinform Res Appl
|
|
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation.
|
20616036
|
Proc. Natl. Acad. Sci. U.S.A.
|
|
Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival.
|
27799870
|
Clin Proteomics
|
|
Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.
|
24240684
|
Oncogene
|
|
Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.
|
20085934
|
J. Clin. Oncol.
|
|
Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure.
|
23045294
|
Eur J Cardiothorac Surg
|
|
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
|
22412141
|
J. Clin. Oncol.
|
|
Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer.
|
27002763
|
Cancer Biomark
|
|
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
|
18154821
|
Ann. Thorac. Surg.
|
|
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
|
18154821
|
Ann. Thorac. Surg.
|
|
Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.
|
29617667
|
Cell Rep
|
|
Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.
|
29129073
|
J. Proteome Res.
|
|
SV40 detection in human tumor specimens.
|
16267039
|
Cancer Res.
|
|
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
|
19960346
|
Cancer Chemother. Pharmacol.
|
|
Telomerase activity in pleural malignant mesotheliomas.
|
21277646
|
Lung Cancer
|
|
The aberrant promoter methylation of BMP3b and BMP6 in malignant pleural mesotheliomas.
|
18949431
|
Oncol. Rep.
|
|
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
|
29617669
|
Cell Rep
|
|
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
|
29925010
|
Cell Rep
|
|
The Immune Landscape of Cancer.
|
29628290
|
Immunity
|
|
The Microbiome in Lung Cancer Tissue and Recurrence-Free Survival.
|
30733306
|
Cancer Epidemiol. Biomarkers Prev.
|
|
The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival.
|
20010871
|
Oncogene
|
|
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.
|
29362358
|
Oncogenesis
|
|
Tissue and exosomal miRNA editing in Non-Small Cell Lung Cancer.
|
29976955
|
Sci Rep
|
|
TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis.
|
16798876
|
Proc. Natl. Acad. Sci. U.S.A.
|
|
Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma.
|
23851502
|
Oncogene
|
|
Tumorigenic properties of alternative osteopontin isoforms in mesothelioma.
|
19285954
|
Biochem. Biophys. Res. Commun.
|
|
Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.
|
21170350
|
PLoS ONE
|
|
Validation of a blood protein signature for non-small cell lung cancer.
|
25114662
|
Clin Proteomics
|
|
Validation of a multiprotein plasma classifier to identify benign lung nodules.
|
25590604
|
J Thorac Oncol
|
|
Variant Ciz1 is a circulating biomarker for early-stage lung cancer.
|
23074256
|
Proc. Natl. Acad. Sci. U.S.A.
|
|
When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
|
30863365
|
Front Endocrinol (Lausanne)
|
|
Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.
|
29313979
|
Int. J. Cancer
|
|
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
|
25488749
|
Cancer Res.
|
|
Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo.
|
22912669
|
PLoS ONE
|
